[Brokerage Focus] CITIC SEC: Expect limited short-term impact from Trump's prescription drug executive order.

Jinwu Finance News | CITIC SEC released a Research Report stating that on May 12, 2025, Trump signed an executive order titled 'Providing U.S. Patients with the Prescription Drug “Most Favored Nation” Price,' aimed at lowering prescription drug prices in the USA market. In the executive order, Trump proposed the 'Most Favored Nation' price, requiring pharmaceutical companies to set their drug sales prices in the USA at the same level as the lowest prices in comparable developed countries. At the same time, Trump also proposed to enhance the transparency of pharmaceutical prices in the USA and reduce the profit margins for 'middlemen' represented by PBM. We believe that the implementation of this executive order will be challenging, and its short-term impact on the Industry is expected to be limited.